Evolution of TALENs
Engineered transcriptional activator-like effectors (TALEs) are versatile tools for genome manipulation with applications in research and clinical contexts. One current drawback of TALEs is that the 5′ nucleotide of the target is specific for thymine (T). TALE domains with alternative 5′ nucleotide specificities could expand the scope of DNA target sequences that can be bound by TALEs. Another drawback of TALEs is their tendency to bind and cleave off-target sequence, which hampers their clinical application and renders applications requiring high-fidelity binding unfeasible. This disclosure provides methods and strategies for the continuous evolution of proteins comprising DNA-binding domains, e.g., TALE domains. In some aspects, this disclosure provides methods and strategies for evolving such proteins under positive selection for a desired DNA-binding activity and/or under negative selection against one or more undesired (e.g., off-target) DNA-binding activities. Some aspects of this disclosure provide engineered TALE domains and TALEs comprising such engineered domains, e.g., TALE nucleases (TALENs), TALE transcriptional activators, TALE transcriptional repressors, and TALE epigenetic modification enzymes, with altered 5′ nucleotide specificities of target sequences. Engineered TALEs that target ATM with greater specificity are also provided.
1. A protein comprising an amino acid sequence that is at least 80% identical to the amino acid sequence LTPX 1 QVVAIAX 2 X 3 X 4 GGX 5 X 6 ALETVQRLLPVLCQX 7 HG (SEQ ID NO: 2),
wherein X 1 is D, E, or A, wherein X 2 is S or N, wherein X 3 is N or H, wherein X 4 is G, D, I, or N, wherein X 5 is K or R, wherein X 6 is Q or P, and wherein X 7 is D or A,
wherein the amino acid sequence comprises one or more amino acid substitutions selected from the group consisting of T2A, P3L, P3S, X 1 4G, X 1 4K, X 1 4N, X 2 11K, X 2 11Y, X 3 12H, X 4 13K, X 4 13H, G15S, X 5 16R, X 6 17P, T21A, L26F, P27S, V28G, Q31K, X 7= S, D32E, and H33L, and
wherein the protein binds to a target sequence of a DNA molecule.
2. The protein of claim 1 , wherein the amino acid sequence is at least 85% identical to the amino acid sequence of SEQ ID NO: 2.
3. The protein of claim 1 , wherein the protein comprises a plurality of amino acid sequences that are at least 85% identical to the amino acid sequence of SEQ ID NO: 2.
4. The protein of claim 3 , wherein the plurality of amino acid sequences form a TALE repeat array.
5. A method comprising contacting a DNA molecule comprising a target sequence with the protein of claim 1 under conditions suitable for the protein to bind the target sequence.
6. The protein of claim 1 , wherein the amino acid sequence comprises one or more amino acid substitutions selected from the group consisting of P3L, X 1 4G, X 1 4K, X 2 11Y, X 5 16R, X 6 17P, T21A, and L26F.
7. The protein of claim 1 , wherein the amino acid sequence comprises one or more amino acid substitutions selected from the group consisting of P3S, X 1 4K, X 3 12H, X 5 16R, and L26F.
8. The protein of claim 1 , wherein the amino acid sequence comprises one or more amino acid substitutions selected from the group consisting of X 1 4N, X 1 4K, X 2 11K, G15S, X 5 16R, L26F, P27S, A32S, D32E, and H33L.
9. The protein of claim 1 , wherein the amino acid sequence comprises one or more amino acid substitutions selected from the group consisting of T2A, P3L, X 1 4K, X 3 12H, V28G, and Q31K.
10. The protein of claim 1 , wherein the amino acid sequence comprises one or more amino acid substitutions selected from the group consisting of X 1 4N, X 1 4K, X 2 11K, X 5 16R, T21A, and L26F.
11. The protein of claim 1 , wherein the amino acid sequence comprises one or more amino acid substitutions selected from the group consisting of ABG, X 4 13K, X 4 13H, A18G, E20G, Q23K, L26A, H33P, H33Y, and G34S.
12. The protein of claim 3 , wherein the plurality of amino acid sequences comprises at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 25, at least 30, at least 40, or at least 50 amino acid sequences.
13. The protein of claim 3 , wherein the plurality of amino acid sequences are directly adjoined to each other without a linker.
14. The protein of claim 13 , wherein the plurality of amino acid sequences form a TALE repeat array.
15. The protein of claim 3 , wherein the amino acid sequence is at least 80% identical to the amino acid sequence of SEQ ID NO: 6, wherein the amino acid sequence comprises one or more amino acid substitutions selected from the group consisting of K16R, K5OR, L94F, T104A, P173L, L196F, K220R, L230F, A236S, N249Y, Q255P, T259A, D276G, L332F, Q337K, H373L, P377L, N386H, G389S, P401S, D406E, P411S, D412N, V436G, E446K, N453K, N455K, K458R, and P513L.
16. The protein of claim 15 , wherein the amino acid sequence is at least 85% identical to the amino acid sequence provided in SEQ ID NO: 6.
17. The protein of claim 15 , wherein the amino acid sequence comprises amino acid substitutions:
(a) K5OR and L230F;
(b) L230F;
(c) L230F and N249Y;
(d) Q255P;
I T259A;
(f) D276G, E446K, and P513L; or
(g) P377L.
18. The protein of claim 15 , wherein the amino acid sequence comprises amino acid substitutions:
(a) K5OR and N453K;
(b) L332F and K458R;
(c) N386H;
(d) P411S and N453K;
I N453K;
(f) E446K; or
(g) K458R.
19. The protein of claim 15 , wherein the amino acid sequence comprises amino acid substitutions:
(a) K16R, G389S, and E446K;
(b) L94F;
(c) L196F, G389S, P401S, and E446K;
(d) K220R;
I A236S, G389S, and E446K;
(f) H373L and D412N;
(g) G389S, D406E, and E446K;
(h) D412N; or
(i) N455K.
20. The protein of claim 15 , wherein the amino acid sequence comprises amino acid substitutions:
(a) T104A, Q337K, N386H, and E446K;
(b) P173L, Q337K, N386H, E446K, and V436G; or
(c) Q337K, N386H, E446K, and V436G.